Absci Announces Pricing of Public Offering of Common Stock

▤ Summary

Absci announced the pricing of an underwritten public offering of 16.67 million common shares at $3.00 per share. The company expects to raise about $50 million in gross proceeds before fees and expenses. Absci plans to use the net proceeds to advance internally developed programs, invest in its Integrated Drug Creation platform, and support working capital and general corporate needs. The offering is expected to close on or about July 25, 2025, subject to customary conditions.

$ Funding

▦ Linked Companies